These findings demonstrate that the in vivo shikonin treatment can increase the vulnerability of triple-negative breast cancer to cisplatin, and PKM2 might be a potential target to sensitize triple-negative breast cancer cells during chemotherapy. The gene discussed is PKM; the disease is triple-negative breast carcinoma.